N-003 Follow-up Form 
N-004 Flow Sheet 
N-005 Chemotherapy Form 
N-006 Neuroradiology Form 
N-007 Toxicity Form 
N-008 Death Form 
Adverse Reaction Reporting Form 
Every month while receiving protocol 
treatment and at completion of protocol 
treatment, then every three months 
until disease progrssion or initiation of 
alternative treatment 
Within five days for reportable toxic 
events 
At death 
11.0 BIBLIOGRAPHY 
1. Gabrilove JL, Jakubowski A. Hematopoietic growth factors: biology and clinical application. 
Monograph J Natl Cancer Inst. 10:73-77, 1990. 
2. Kelso A. Cytokines: structure and function and synthesis. Current Opinion in Immunology 
2(2):2 15-225, 1989. 
3. Borden EC, Sondel PM. Lymphokines and cytokines as cancer treatment. Immunotherapy 
realized. Cancer 65 (3 Suppl):800-814, 1990. 
4. Rosenberg SA, Lotze MT, Mule JJ. New approaches to the immunotherapy of cancer. Ann 
Intern Med 108:853-864, 1988. 
5. Lotze MT, Change AE, Seipp CA, et al. High-dose recombinant interleukin-2 in the treatment of 
patients with disseminated cancer: responses, treatment-related morbidity and histologic findings. JAMA 
256:3117-3124, 1986. 
6. Pizza G, Viza D, De Vinci C, Paschuchi JM, Busutti L, Bergami T. Intralymphatic administration 
of interleukin-2 (IL-2) in cancer patients: a pilot study. Cytokine Research 7(l):45-48, 1988. 
7. Sama G, Collins J, Figlin R, Robertson P, Altrock B, Abels R. A pilot study of intralymphatic 
interleukin-2. II Clinical and biological effects. J Biological Response Modifiers 9(l):81-86, 1990. 
8. Gandolfi L, Solmi L, Pizza GC, Bertoni F, Muratori R, De Vinci C, Bacchini P, Morelli MC, 
Corrado G. Intratumoral echo-guided injection of interleukin-2 and cytokine-activated killer cells in 
hepatocellular carcinoma. Hepato-Gastroenterology 36(5):352-356, 1989. 
9. Bubenik J, Viotenok NN, Kieler J, Prassolov VS, Chumakov PM, Bubenikova D, Simova J, 
Jandlova T. Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits 
growth of human tumors in nu/nu mice. Immunology Letters 19(4):279-282, 1988. 
10. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, 
Vogelstein B, Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the 
generation of an anti-tumor response. Cell 60:387-403, 1990. 
1 1 . Gansbacher B, Zier K, Daniels B, Caronin K, Bannerji R, Gilboa E. Interleukin-2 gene transfer 
into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172: 1217-1223, 
1990. 
12. Watanabe Y, Kuribayashi K, Miyatake S, Nishihara K, Nakayama EL, Taniyama T, Sakata TA. 
Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in 
reduced tumorigenicity by augmented anti-tumor immunity. Proc. Natl Acad Sci 86:9456-9460, 1989. 
[632] 
Recombinant DNA Research, Volume 19 
